Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors

By Yasuo Uchida, S. Ohtsuki, Y. Katsukura, Chiemi Ikeda, Takashi Suzuki, J. Kamiie, T. Terasaki. Journal of Neurochemistry, 2011

802 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors (2017, background): “, 2011), whereas P-gp is more abundantly expressed in rodents (Kamiie et al., 2008; Uchida et al., 2011).”
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options (2020, background): “For this option, it is important to note that Pgp is not the only major efflux transporter at the human BBB and that BCRP is even more highly expressed (Uchida et al., 2011).”
Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation (2012, positive): “This technology will also greatly benefit the field, allowing absolute quantification of TJ proteins in physiological and various pharmacological situations, as recently proposed [180].”
In vitro models of the blood–brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use (2016, background): “On the other hand, the proteins expressed by bovine and porcine models differ in sequence from their human homologues and this may in some cases translate to differences in affinity and transport rate.(50,158) This also poses a challenge when investigating therapeutic antibodies designed to target B”